NCT02704533View on ClinicalTrials.gov

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

October 19, 2018

Study Completion Date

December 31, 2018

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54

BIOLOGICAL

PfSPZ Challenge (NF54)

Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54

BIOLOGICAL

PfSPZ Challenge (7G8)

Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

OTHER

Normal saline

0.9% sodium chloride

Trial Locations (1)

D-72074

Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27, Tübingen

Sponsors
All Listed Sponsors
collaborator

Institute of Tropical Medicine, University of Tuebingen

OTHER

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

German Center for Infection Research

OTHER

lead

Sanaria Inc.

INDUSTRY

NCT02704533 - Sequential Optimization of Dose and Schedule of PfSPZ Vaccine | Biotech Hunter | Biotech Hunter